observed strongly reduced tumour outgrowth in an in vivo MCC xenograft mouse model.Taking the results together, Adcitmer â is an interesting addition to the growing list of targeted therapies, including inhibitors of mammalian target of rapamycin, 9 phosphoinositide 3-kinase 9 and lysine-specific demethylase 1, 10 that are effective in preclinical MCC models. Given these encouraging results, further studies are needed to evaluate the drug-safety profile of Adcitmer â , particularly its effects on normal, CD56expressing cell populations, especially natural killer cells and neuronal cell types. Reduced natural killer cell function might influence antitumour and antiviral responses, 8 and peripheral neuropathy is a common side-effect in patients treated with MMAE. 6 With a favourable drug-safety profile, Adcitmer â should also be considered as a treatment option for other CD56-expressing tumours, such as blastic plasmacytoid dendritic cell neoplasms. As combination therapies are likely to be more effective, it is of interest whether Adcitmer â can stimulate the immune system (e.g. by releasing tumour antigens) to enhance the efficacy of immune checkpoint inhibitors.